Home >> Tag Archives: Quest Diagnostics— (page 2)

Tag Archives: Quest Diagnostics—

DiaSorin enters molecular market with Focus buy

April 7, 2016—DiaSorin will buy Quest’s Focus Diagnostics immunodiagnostic and molecular diagnostic products business for $300 million in cash. The deal includes all the tangible and intangible assets of Focus used to develop, manufacture, and distribute its molecular diagnostic products and its traditional immunoassay ELISA products, including relevant intellectual property, contracts, and customer list. Focus’ products include the Simplexa molecular ...

Read More »

Genomic test service for hematologic malignancies, 6/15

June 2015—LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring, and selection of treatment for myeloid neoplasms is now available from Quest Diagnostics. The lab-developed test uses next-generation sequencing, polymerase chain reaction, and other techniques to interrogate DNA from leukocytes in blood or bone marrow specimens for the presence of mutations in 30 genes most frequently associated with myeloid neoplasms.

Read More »

Quest, CDC collaborate to improve hepatitis care, 3/15

March 2014—Quest Diagnostics will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis, and treatment for four strains of viral hepatitis in the U.S. Under terms of the multiyear contract, Quest will provide CDC researchers with analytics expertise and access to the company’s national Health Trends database of de-identified clinical testing hepatitis data.

Read More »

Partners: UCSF, Quest, 4/14

April 2014—UC San Francisco and Quest Diagnostics formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine for improved patient care, treatment, and outcomes.

Read More »

BRCA genetic testing, 12/13

December 2013—Quest Diagnostics now offers BRCAvantage, a suite of four lab-developed genetic tests that identify mutations in BRCA1 and BRCA2 genes. The BRCAvantage test is performed using next-generation sequencing and multiplex ligation-dependent probe amplification to detect all published deleterious mutations in BRCA1 and BRCA2.

Read More »